A paradigm shift in tumour response evaluation of targeted therapy: The assessment of novel drugs in exploratory clinical trials

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 338-344

  Cousin, Sophie ^a   Taieb, Sophie ^b   Penel, Nicolas ^a,c  

^a CENTRE OSCAR LAMBRET   (France)

^b Oscar Lambret Cancer Center   (France)

^c UNIV LILLE   (France)

Author keywords

antitumour activity; phase II screening trial; standardized endpoint

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER INHIBITION; CONTRAST ENHANCEMENT; DRUG TARGETING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; DYNAMIC CONTRAST ENHANCED ULTRASONOGRAPHY; ECHOGRAPHY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; DRUG DESIGN; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84859849488     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283528b73     Document Type: Review

References (21)

1. Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true endpoint: insights from the breast and colorectal cancer literature. Ann Oncol 2010; 21:7-12.
2. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. New Engl J Med 2009; 361: 1164-1172.
3. Flaherty K, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
4. Ferté C, Soria JC, Penel N. Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. PLoS One 2011; 6:e16633.
5. Gomez-Roca C, Koscielny S, Ribrag V, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 2011; 47:2512-2516.
6. Postel-Vinay S, Arkenau HT, Olmos D, et al. Clinical benefit in phase I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 2009; 100:1373-1378.
7. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303:1062-1069.
8. Dudeck O, Zeile M, Reichardt P, Pink D. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 2011; 22:1828-1833.
9. Ott K, Herrmann K, Schuster T, et al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol 2011; 18:3316-3323.
10. Jiang T, Kambadakone A, Kukami NM, et al. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012; 47:11-17.
11. Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumor response to therapy. Lancet Oncol 2010; 11:92-102.
12. Martincich L, Bertotto I, Montemurro F, et al. Variation of breast vascular maps on dynamic contrast-enhanced MRI after primary chemotherapy of locally advanced breast cancer. AJR Am J Roentgenol 2011; 195:1214-1218.
13. Meng X, Loo BW Jr, Ma L, et al. Molecular imaging 11C-PD153035 PET/CT predicts survival in nonsmall lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med 2011; 32:1573-1579.
14. Dicker DT, Kahn N, Flaherty KY, et al. Hyperspectral imaging: a noninvasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with RAF inhibitor. Cancer Biol Ther 2011; 12:326-334.
15. Lassau N, Chami L, Chebil M, et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and antiangiogenic treatments. Disc Med 2011; 11:18-24.
16. Von Hoff DD. There are no bad anticancer agents, only bad clinical trial design: twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998; 4:1079-1086. (Pubitemid 28213317)
17. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877-4883.
18. Kovalchik S, Mietlowski W. Statistical methods for a phase II oncology trial with growth modulation index (GMI) endpoint. Contemp Clin Trials 2011; 32:99-107.
19. Buyse M, Quinaux E, Hendlisz A, et al. Progression-free survival ratio as endpoint for phase II trials in advanced solid tumors. J Clin Oncol 2011; 29:e451-e452.
20. Fridlyand J, Kaiser LD, Fyfe G. Analysis of tumor burden versus progression-free survival for phase II decision making. Contemp Clin Trials 2011; 32:446-452.
21. Pacey S, Ratain MJ, Flaherty KT, et al. Efficacy and safety of sorafenib in a subset of patients of patients with advance soft tissue sarcoma from a phase II randomized discontinuation trial. Invest New Drugs 2011; 29:481-488.